AbbVie Inc.

09/16/2021 | Press release | Distributed by Public on 09/16/2021 06:11

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis